11:14 AM EDT, 05/20/2024 (MT Newswires) -- Lisata Therapeutics ( LSTA ) said Monday it has obtained a full pediatric waiver from the European Medicines Agency for investigational drug certepetide in pancreatic cancer.

The agency granted the waiver based on the recommendation of its pediatric committee, which cited that pancreatic cancer occurs exclusively in adults, the company said.

The waiver eliminates the need for clinical studies of certepetide in children for pancreatic cancer, reducing the clinical trial load and overall development costs for achieving market registration in Europe, Lisata said.

Shares of the company were up 3.5% in recent Monday trading.

Price: 2.87, Change: +0.10, Percent Change: +3.50